kabutan

K Pharma,Inc.(4896) Summary

4896
TSE Growth
K Pharma,Inc.
616
JPY
-13
(-2.07%)
Dec 12, 3:30 pm JST
3.95
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
620
Dec 12, 11:56 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.54
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
629 JPY 4.04 USD
Previous Close Dec 11
629 JPY 4.02 USD
High Dec 12, 9:14 am
632 JPY 4.06 USD
Low Dec 12, 2:00 pm
611 JPY 3.92 USD
Volume
63,800
Trading Value
0.04B JPY 0.25M USD
VWAP
621.93 JPY 3.99 USD
Minimum Trading Value
61,600 JPY 395 USD
Market Cap
7.15B JPY 0.05B USD
Number of Trades
133
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
503
1-Year High Mar 26, 2025
14,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 360,800
Nov 28, 2025 0 375,400
Nov 21, 2025 0 403,600
Nov 14, 2025 0 461,700
Nov 7, 2025 0 457,200
Company Profile
K Pharma, Inc. engages in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company originated from Keio University.
Sector
Pharmaceuticals
K Pharma, Inc. is a company specializing in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company primarily focuses on the central nervous system disease area, developing both iPS cell-based drug discovery and regenerative medicine businesses. In iPS drug discovery, K Pharma is advancing the development of treatments for intractable diseases such as ALS and Alzheimer's disease. In regenerative medicine, the company is working on developing iPS cell-derived neural progenitor cell transplantation therapies for neurological disorders like spinal cord injury and cerebral infarction. Through collaborations with universities and research institutions, K Pharma commercializes basic research findings and has established a revenue model based on licensing agreements with pharmaceutical companies. The company aims for early clinical application, promoting the development of groundbreaking treatments in areas with high unmet medical needs.